Medical Device News Magazine

Healthy.io Announces Collaboration with Boehringer Ingelheim to Increase Access to Testing for Kidney Disease

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Healthy.io, the global leader in transforming the smartphone camera into a medical device, today announced the launch of a program with Boehringer Ingelheim Pharmaceuticals, Inc, a leading research-driven pharmaceutical company, that will support at-home testing and provide educational information for patients at risk of chronic kidney disease (CKD).

Through this collaboration, Boehringer Ingelheim will work with Healthy.io’s Minuteful Kidney™ test kit to explore the operational aspects of an at-home UACR (urine albumin-to-creatinine ratio) test kit – the first and only FDA-cleared, smartphone powered at-home ACR test – to at-risk, previously untested patients. This will help engage these patients in their kidney health by conducting a smartphone-powered test at the time and place of their choosing as a step-in screening for earlier identification of CKD.

“Minuteful Kidney is a catalyst to increase ACR testing at scale and support early detection of CKD,” said Paula LeClair, U.S. General Manager at Healthy.io. “Increasing test-adherence rates across all demographics and socio-economic groups leads to earlier detection of CKD and provides a path to care for those who need it. This is a true win-win – better health outcomes for patients, as well as potentially reduced healthcare costs.”

“Early screening and diagnosis is critical in delaying CKD progression, and may help reduce the potential for serious complications down the road,” said Lennart Jungersten, Senior Vice President, Medicine and Regulatory Affairs, Boehringer Ingelheim Pharmaceuticals, Inc. “By collaborating with Healthy.io, the ultimate goal is to increase testing for CKD so that those impacted can be evaluated for the appropriate care management.”

CKD is referred to as a “silent killer” because it often doesn’t have symptoms until very late stages. One in three Americans are at risk, including those with diabetes and hypertension. Yet most don’t know they have the condition until it progresses to end-stage renal disease (ESRD), eventually requiring dialysis and/or a kidney transplant. According to guideline-based care, people at risk should complete an annual UACR test, yet 80% do not.

Prior Healthy.io programs conducted in collaboration with leading health plans and provider systems have shown that at home testing with Minuteful Kidney raised testing adherence up to 50% at scale across previously untested populations irrespective of demographic and socioeconomic differences. This is particularly important as chronic, preventable illnesses disproportionately affect people of color. According to the National Kidney Foundation, Black or African Americans are almost 4 times more likely, and Hispanics or Latinos are 1.3 times more likely, to have kidney failure compared to white Americans.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”